News | May 22, 2015

EVOLVE Trials Show Positive Results with Boston Scientific’s Synergy Stent

EVOLVE I examines Synergy versus Promus Element Plus stent; EVOLVE II studies Synergy in diabetic patients

Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results

May 22, 2015 — Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse cardiac events reported between years three and four. The study results were presented at EuroPCR 2015 by Prof. Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.

Findings from year four of the EVOLVE Trial include the following key performance measures:

  • The target lesion revascularization (TLR) rate was 1.1 percent compared to 6.1 percent for the Promus Element Plus Stent System (p=0.07); and
  • No definite or probable stent thrombosis (ST) was observed.

 

"These long-term data from the EVOLVE Trial are quite important as they highlight the sustained safety and performance of the Synergy Stent," said Meredith.  "We continue to be encouraged by the consistently positive clinical data that point to the potential for improved healing with the Synergy Stent compared to durable polymer drug-eluting stents."

The EVOLVE Trial is the first human use, prospective, randomized, single-blind study evaluating the non-inferiority of the Synergy Stent, which employs an ultrathin bioabsorbable polymer coating applied to the abluminal (outer) surface of the stent. The comparator, the Boston Scientific Promus Element Plus Stent System, utilizes a durable polymer coating applied to the entire stent (inner and outer) surface. EVOLVE is the first in a continuing cadence of clinical trials evaluating the performance of the Synergy Stent in a range of patients.

In addition to these long-term data from the EVOLVE Trial, one-year findings from the EVOLVE II pivotal trial of 466 patients with diabetes treated with the Synergy Stent were presented by Stephan Windecker M.D., chief of cardiology and head of invasive cardiology at the Swiss Cardiovascular Center in Bern, Switzerland. Patients with diabetes face an increased risk of heart disease, stroke and myocardial infarction. The data presented for patients with diabetes include the following:

  • The TLR rate was 4.4 percent; and
  • Definite/probable ST was 1.1 percent at one year, with no definite/probable ST events after the first week post percutaneous coronary intervention (PCI).

 

The EVOLVE II Trial includes a global, multi-center, randomized, single-blind, non-inferiority pivotal trial designed to evaluate the safety and performance of the SYNERGY Stent System compared to the Promus Element Plus Stent System. The trial enrolled 1,684 patients in 125 sites worldwide and is part of a rigorous clinical program designed to support the submission for U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the Synergy Stent.

The EVOLVE II Trial also includes a non-randomized, single-arm diabetes study. The EVOLVE II Diabetes Substudy pooled patients with diabetes randomized to the Synergy arm in the EVOLVE II pivotal trial with patients enrolled in the non-randomized single-arm diabetes study as pre-specified in the study protocol.  

Patients in the EVOLVE II Trial demonstrated clinical and angiographic complexity to a degree not observed in prior U.S. pivotal trials for drug-eluting stents (DES). More than 25 percent of patients had non-ST elevation myocardial infarction (NSTEMI) and approximately 75 percent of patients had AHA/ACC class B2/C coronary lesions. As previously reported, EVOLVE II met its primary endpoint, demonstrating non-inferiority of Synergy versus the Promus Element Plus Stent for 12-month target lesion failure in the overall patient population.   

For more information: www.bostonscientific.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init